股本结构
单位：万股
| 公告日期 | 2024-03-01 | 2023-11-13 | 2023-11-13 | 2023-08-14 | 2023-08-14 | 2023-05-11 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1409.89 | 1395.73 | 330.48 | 328.00 | 328.25 | 327.13 |
| 普通股本 | 1409.89 | 1395.73 | 330.48 | 328.00 | 328.25 | 327.13 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-03 | 2023-09-30 | 2023-08-07 | 2023-06-30 | 2023-05-04 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-01 | 1409.89 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Vesting of restricted stock units, net of withholding for tax, and shares issued under employee share purchase plan
Issuance of common stock in at-the-market offering, net of $5 in issuance costs
Issuance of common stock and pre-funded warrants in Private Placement, net of $5,486 in issuance costs
Cashless exercise of pre-funded warrants
|
2023-12-31 |
| 2023-11-13 | 1395.73 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-13 | 330.48 | 未披露 |
更多>>
From July 1, 2023 to September 30, 2023
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
|
2023-09-30 |
| 2023-08-14 | 328.00 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-08-14 | 328.25 | 未披露 |
更多>>
From April 1, 2023 to June 30, 2023
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
|
2023-06-30 |
| 2023-05-11 | 327.13 | 未披露 | 定期报告 | 2023-05-04 |
| 2023-05-11 | 327.13 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Issuance of common stock under at-the-market offering, net of $5 in issuance costs
Redemption of convertible preferred stock
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
|
2023-03-31 |
| 2023-03-14 | 326.43 | 未披露 | 定期报告 | 2023-03-01 |
| 2023-02-10 | 325.19 | 未披露 |
更多>>
On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).
|
2023-02-13 |
| 2023-02-10 | 5853.37 | 未披露 | 定期报告 | 2023-02-10 |
| 2022-11-25 | 5803.58 | 0.30 | 定期报告 | 2022-11-16 |
| 2022-11-14 | 5803.58 | 未披露 |
更多>>
From JULY 1, 2022 to September 30, 2022
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
|
2022-09-30 |
| 2022-08-12 | 5800.56 | 未披露 | 定期报告 | 2022-08-04 |
| 2022-08-12 | 5800.56 | 未披露 |
更多>>
From APRIL 1,2022 to JUNE 30, 2022
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
|
2022-06-30 |
| 2022-06-17 | 5797.52 | 未披露 | 定期报告 | 2022-06-14 |
| 2022-06-17 | 5790.85 | 未披露 | 定期报告 | 2022-05-25 |
| 2022-05-12 | 5738.93 | 未披露 | 定期报告 | 2022-05-11 |
| 2022-05-12 | 5790.85 | 未披露 |
更多>>
From JANUARY 1, 2021 to March 31, 2022
Vesting of restricted stock units, net of withholding tax
Issuance of commitment shares in March 2022
Issuance of common stock, net of $48 in issuance costs
|
2022-03-31 |
| 2022-03-17 | 5616.56 | 未披露 | 定期报告 | 2022-03-02 |
| 2022-03-17 | 5357.77 | 未披露 |
更多>>
From DECEMBER 31, 2020 to DECEMBER 31, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee share purchase plan
Issuance of common stock, net of $4,215 issuance costs
|
2021-12-31 |
| 2021-11-10 | 5351.79 | 未披露 | 定期报告 | 2021-11-03 |
| 2021-11-10 | 5351.06 | 未披露 |
更多>>
From JULY 1, 2021 to SEPTEMBER 30, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of common stock under at-the-market offering, net of $184 issuance costs
|
2021-09-30 |
| 2021-08-12 | 5151.18 | 未披露 |
更多>>
From April 1, 2021 to June 30, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
|
2021-06-30 |
| 2021-06-07 | 5138.74 | 未披露 | 定期报告 | 2021-05-27 |
| 2021-05-06 | 5138.66 | 未披露 |
更多>>
From JANUARY 1, 2021 to MARCH 31, 2021
Exercise of options and vesting of restricted stock units
Issuance of common stock under at-the-market offering, net of $814 issuance costs Issuance of common stock through a registered direct offering, net of $3,177 issuance costs
|
2021-03-31 |
| 2021-03-04 | 5132.92 | 未披露 | 定期报告 | 2021-02-25 |
| 2021-02-16 | 5132.69 | 未披露 |
更多>>
On February 16, 2021, VYNE Therapeutics Inc. (the “Company”) completed its previously announced reverse stock split. As a result of the reverse stock split, every four shares of issued and outstanding common stock was automatically combined into one issued and outstanding share of common stock, without any change in the par value per share.Following the reverse stock split, there are now 51,326,891 shares of common stock issued and outstanding.
|
2021-02-16 |
| 2021-01-28 | 18895.65 | 未披露 |
更多>>
1.Common stock offered by the company 21,097,046 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 167,859,461 shares of common stock outstanding as of September 30, 2020.
|
2021-01-28 |
| 2020-11-05 | 16787.86 | 未披露 | 定期报告 | 2020-10-30 |
| 2020-11-05 | 16785.95 | 未披露 |
更多>>
From July 1, 2020 to September 30, 2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
|
2020-09-30 |
| 2020-08-06 | 16769.06 | 未披露 | 定期报告 | 2020-07-30 |
| 2020-08-06 | 16768.38 | 未披露 |
更多>>
From April 1,2020 to June 30,2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of Ordinary Shares through a public offering, net of $3,903 issuance costs
Issuance of stock related to merger
|
2020-06-30 |
| 2020-06-22 | 16762.23 | 未披露 | 定期报告 | 2020-06-10 |
| 2020-06-09 | 16309.55 | 未披露 |
更多>>
1.Common stock offered by us 27,050,000 shares of common stock
2.The number of shares of common stock to be outstanding after this offering is based on 136,045,543 shares of common stock outstanding as of March 31, 2020
|
2020-06-09 |
| 2020-05-11 | 13625.71 | 未披露 | 定期报告 | 2020-04-29 |
| 2020-05-11 | 6150.11 | 未披露 |
更多>>
From JANUARY 1, 2020 to March 31, 2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of stock related to merger
|
2020-03-31 |
| 2020-03-03 | 2443.86 | 未披露 | 定期报告 | 2020-02-14 |
| 2020-03-03 | 2440.26 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs
Vesting of restricted stock units, net of taxes withheld
|
2019-12-31 |
| 2020-01-06 | 2427.22 | 未披露 | 定期报告 | 2019-12-16 |
| 2019-10-31 | 2398.38 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs
|
2019-09-30 |
| 2019-08-01 | 2395.31 | 未披露 | 定期报告 | 2019-07-15 |
| 2019-08-01 | 2394.44 | 未披露 |
更多>>
from March 31, 2019 to June 30,2019
Issuance of common stock on exercise of stock options
Issuance of common stock under at-the-market offering, net of commissions and offering costs
|
2019-06-30 |
| 2019-05-10 | 2393.58 | 未披露 | 定期报告 | 2019-04-26 |
| 2019-05-10 | 2392.88 | 未披露 | 定期报告 | 2019-04-15 |
| 2019-05-02 | 2367.22 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs of $229
|
2019-03-31 |
| 2019-02-28 | 2325.82 | 未披露 | 定期报告 | 2019-02-15 |
| 2019-02-28 | 2323.32 | 未披露 |
更多>>
From December 31, 2017 to December 31, 2018
Conversion of preferred stock to common stock
Issuance of common stock under public offering, net
Issuance of common stock on exercise of stock options
|
2018-12-31 |
| 2018-11-07 | 2323.22 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-01 | 2297.80 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-09 | 2297.80 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-28 | 2297.80 | 未披露 | 定期报告 | 2018-02-28 |
| 2018-01-26 | 2192.80 | 未披露 |
更多>>
1.Common stock offered 7,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 14,927,998 shares of common stock outstanding as of September 30, 2017
3.a 1 for 2.6975 reverse stock split of our capital stock effected on January 8, 2018
|
2018-01-25 |
| 2018-01-12 | 529.86 | 2597.53 |
更多>>
from December 31, 2016 to September 30, 2017
Issuance of Series C convertible preferred stock, net of issuance costs of $173 (unaudited)
Issuance of common stock upon exercise of stock options (unaudited)
|
2017-09-30 |
| 2018-01-12 | 528.01 | 1412.09 | 定期报告 | 2016-12-31 |
| 2017-12-28 | 1424.30 | 1412.09 |
更多>>
from January 1, 2015 to December 31, 2015
Issuance of Series A convertible preferred stock
Issuance of Series B convertible preferred stock, net of issuance costs of $179
Exercise of unvested stock options
|
2015-12-31 |
From December 31,2022 to December 31,2023
Vesting of restricted stock units, net of withholding for tax, and shares issued under employee share purchase plan
Issuance of common stock in at-the-market offering, net of $5 in issuance costs
Issuance of common stock and pre-funded warrants in Private Placement, net of $5,486 in issuance costs
Cashless exercise of pre-funded warrants
From July 1, 2023 to September 30, 2023
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
From April 1, 2023 to June 30, 2023
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
From January 1, 2023 to March 31, 2023
Issuance of common stock under at-the-market offering, net of $5 in issuance costs
Redemption of convertible preferred stock
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
On February 10, 2023, VYNE Therapeutics Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect a one-for-eighteen (1:18) reverse stock split of its outstanding common stock, effective as of February 10, 2023 (the “Reverse Stock Split”).
From JULY 1, 2022 to September 30, 2022
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
From APRIL 1,2022 to JUNE 30, 2022
Vesting of restricted stock units, net of withholding tax and shares issued under employee stock purchase plan
From JANUARY 1, 2021 to March 31, 2022
Vesting of restricted stock units, net of withholding tax
Issuance of commitment shares in March 2022
Issuance of common stock, net of $48 in issuance costs
From DECEMBER 31, 2020 to DECEMBER 31, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee share purchase plan
Issuance of common stock, net of $4,215 issuance costs
From JULY 1, 2021 to SEPTEMBER 30, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of common stock under at-the-market offering, net of $184 issuance costs
From April 1, 2021 to June 30, 2021
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
From JANUARY 1, 2021 to MARCH 31, 2021
Exercise of options and vesting of restricted stock units
Issuance of common stock under at-the-market offering, net of $814 issuance costs Issuance of common stock through a registered direct offering, net of $3,177 issuance costs
On February 16, 2021, VYNE Therapeutics Inc. (the “Company”) completed its previously announced reverse stock split. As a result of the reverse stock split, every four shares of issued and outstanding common stock was automatically combined into one issued and outstanding share of common stock, without any change in the par value per share.Following the reverse stock split, there are now 51,326,891 shares of common stock issued and outstanding.
1.Common stock offered by the company 21,097,046 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 167,859,461 shares of common stock outstanding as of September 30, 2020.
From July 1, 2020 to September 30, 2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
From April 1,2020 to June 30,2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of Ordinary Shares through a public offering, net of $3,903 issuance costs
Issuance of stock related to merger
1.Common stock offered by us 27,050,000 shares of common stock
2.The number of shares of common stock to be outstanding after this offering is based on 136,045,543 shares of common stock outstanding as of March 31, 2020
From JANUARY 1, 2020 to March 31, 2020
Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan
Issuance of stock related to merger
from December 31, 2018 to December 31, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs
Vesting of restricted stock units, net of taxes withheld
from June 30, 2019 to September 30, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs
from March 31, 2019 to June 30,2019
Issuance of common stock on exercise of stock options
Issuance of common stock under at-the-market offering, net of commissions and offering costs
From December 31, 2018 to March 31, 2019
Issuance of common stock on exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan
Issuance of common stock under at-the-market offering, net of commissions and offering costs of $229
From December 31, 2017 to December 31, 2018
Conversion of preferred stock to common stock
Issuance of common stock under public offering, net
Issuance of common stock on exercise of stock options
1.Common stock offered 7,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 14,927,998 shares of common stock outstanding as of September 30, 2017
3.a 1 for 2.6975 reverse stock split of our capital stock effected on January 8, 2018
from December 31, 2016 to September 30, 2017
Issuance of Series C convertible preferred stock, net of issuance costs of $173 (unaudited)
Issuance of common stock upon exercise of stock options (unaudited)
from January 1, 2015 to December 31, 2015
Issuance of Series A convertible preferred stock
Issuance of Series B convertible preferred stock, net of issuance costs of $179
Exercise of unvested stock options